IMMULAB - Immunotherapy With Pembrolizumab in Combination With Local Ablation in Hepatocellular Carcinoma (HCC)

PHASE2CompletedINTERVENTIONAL
Enrollment

30

Participants

Timeline

Start Date

May 9, 2019

Primary Completion Date

April 30, 2024

Study Completion Date

April 30, 2024

Conditions
Hepatocellular Carcinoma (HCC)
Interventions
DRUG

Pembrolizumab

IV infusion

PROCEDURE

Radio Frequency Ablation (RFA)

Local ablation via RFA will be performed via ultrasound- or CT-guided placement of a needle electrode / probe penetrating into the lesion center

PROCEDURE

Microwave Ablation (MWA)

Local ablation via MWA will be performed via ultrasound- or CT-guided placement of a needle electrode / probe penetrating into the lesion center

RADIATION

Brachytherapy

Local ablation via brachythwerapy will be performed via ultrasound- or CT-guided placement of a needle electrode / probe penetrating into the lesion center

DRUG

Transarterial Chemoembolisation (TACE)

According to Investigator's choice, TACE using drug eluting beads can be performed combined with RFA, MWA or brachytherapy

Trial Locations (1)

30625

Hannover Medical School, Hanover

All Listed Sponsors
lead

Institut für Klinische Krebsforschung IKF GmbH at Krankenhaus Nordwest

OTHER

NCT03753659 - IMMULAB - Immunotherapy With Pembrolizumab in Combination With Local Ablation in Hepatocellular Carcinoma (HCC) | Biotech Hunter | Biotech Hunter